✦ LIBER ✦

Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second-Line Hormonal Therapy (CALGB 9181)

✍ Scribed by Susan Halabi; Mark R. Conaway; Eric J. Small; Nicholas J. Vogelzang; Nancy A. Dawson

Book ID: 114436356
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 291 KB
Volume: 3
Category: Article
ISSN: 1095-5100
DOI: 10.1046/j.1525-1411.2001.31003.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MP-08.05: Usefulness of prostate-specifi

MP-08.05: Usefulness of prostate-specific antigen change as predictor of survival of patients with advanced prostate cancer after hormonal therapy

✍ H. Ehara; T. Katoh; K. Mizutani; K. Nakane; K. Seike; T. Sugawara; S. Katoh; T. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Time to prostate-specific antigen nadir

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

✍ Toni K. Choueiri; Wanling Xie; Anthony V. D'Amico; Robert W. Ross; Jim C. Hu; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 2 views

Pretreatment Serum Level of Neuron Speci

Pretreatment Serum Level of Neuron Specific Enolase (NSE) as a Prognostic Factor in Metastatic Prostate Cancer Patients Treated with Endocrine Therapy

✍ Naoto Kamiya; Koichiro Akakura; Hiroyoshi Suzuki; Shinzou Isshiki; Akira Komiya; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 112 KB

The potential of serum prostate-specific

The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia

✍ C.G. Roehrborn 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Phase 3 randomized trial evaluating seco

Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), intergroup/clinical trials support unit study

✍ Janet R Walczak; Michael A Carducci 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Adrenal androgen levels as predictors of

Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen

✍ Kazutaka Narimoto; Atsushi Mizokami; Kouji Izumi; Shinya Mihara; Kiyoshi Sawada; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB